I-Mab: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über I-Mab Unternehmen

Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

I-Mab Informationen



BörsenkürzelIMAB

Name des UnternehmensNovaBridge Biosciences

IPO-datumJan 17, 2020

CEOFu (Xi-Yong)

Anzahl der mitarbeiter32

WertpapierartDepository Receipt

GeschäftsjahresendeJan 17

AddresseSuite 400, 2440 Research Blvd

StadtROCKVILLE

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl20850

Telefon13016702800

Websitehttp://www.novabridge.com/#/

BörsenkürzelIMAB

IPO-datumJan 17, 2020

CEOFu (Xi-Yong)

Führungskräfte von I-Mab



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Wei Fu

Executive Chairman of the Board

--

Mr. Chun Kwok (Alan) Au

Independent Director

--

Mr. Chia-Hung (Conor) Yang

Independent Director

--

Dr. Phillip Dennis, M.D., Ph.D.

Chief Medical Officer

--

Dr. Xi-Yong (Sean) Fu, Ph.D.

Chief Executive Officer, Director

--

Dr. Robert Lenz, M.D., Ph.D.

Independent Director

--

,

Independent Director

--

,

Chief Business Development Officer, Director

--

Mr. Kyler Lei

Chief Financial Officer

--

Mr. Claire Xu

Senior Vice President - Clinical Development

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Wei Fu

Executive Chairman of the Board

--

Mr. Chun Kwok (Alan) Au

Independent Director

--

Mr. Chia-Hung (Conor) Yang

Independent Director

--

Dr. Phillip Dennis, M.D., Ph.D.

Chief Medical Officer

--

Dr. Xi-Yong (Sean) Fu, Ph.D.

Chief Executive Officer, Director

--

Dr. Robert Lenz, M.D., Ph.D.

Independent Director

--

Umsatzaufteilung

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach RegionUSD

Name

Umsatz

Anteil

China (Mainland)

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Wed, Apr 29

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Everest Medicines Ltd

13.70%

CBC Group

11.45%

Janus Henderson Investors

7.30%

T Investment Ltd

7.07%

HHLR Advisors, Ltd.

5.17%

Andere

55.32%

Aktionäre

Anteil

Everest Medicines Ltd

13.70%

CBC Group

11.45%

Janus Henderson Investors

7.30%

T Investment Ltd

7.07%

HHLR Advisors, Ltd.

5.17%

Andere

55.32%

Aktionärstypen

Aktionäre

Anteil

Corporation

20.77%

Investment Advisor/Hedge Fund

14.37%

Private Equity

11.45%

Hedge Fund

7.48%

Investment Advisor

6.37%

Research Firm

3.54%

Individual Investor

0.56%

Venture Capital

0.31%

Andere

35.15%

Institutionelle Beteiligung



Aktualisiert: Wed, Apr 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2026Q1

119

50.69M

43.94%

-306.69K

2025Q4

112

44.52M

38.63%

+8.34M

2025Q3

108

25.11M

21.79%

-19.02M

2025Q2

118

35.60M

36.28%

-16.36M

2025Q1

125

33.28M

40.75%

-18.83M

2024Q4

137

31.58M

39.04%

-19.85M

2024Q3

150

39.14M

48.39%

-19.95M

2024Q2

195

40.08M

49.56%

-22.86M

2024Q1

267

37.63M

46.01%

-10.84M

2023Q4

298

37.94M

46.39%

-12.75M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Everest Medicines Ltd

15.85M

13.74%

+15.85M

--

Aug 05, 2025

CBC Group

13.24M

11.48%

+1.29M

+10.76%

Jan 29, 2026

Janus Henderson Investors

8.44M

7.32%

+445.26K

+5.57%

Dec 31, 2025

T Investment Ltd

8.17M

7.09%

--

Mar 19, 2025

HHLR Advisors, Ltd.

5.98M

5.19%

--

Dec 31, 2025

Morgan Stanley & Co. LLC

3.61M

3.14%

+2.25M

+165.50%

Dec 31, 2025

Invus Public Equities Advisors, LLC

3.00M

2.6%

+1.83M

+157.30%

Dec 31, 2025

Point72 Asset Management, L.P.

2.30M

1.99%

+2.22M

+2871.64%

Dec 31, 2025

Candriam Luxembourg S.A.

1.62M

1.41%

+7.14K

+0.44%

Jan 31, 2026

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

ALPS Barron's 400 ETF

0.3%

SPDR S&P Emerging Markets Small Cap ETF

0.04%

SPDR S&P China ETF

0.01%

SPDR Portfolio Emerging Markets ETF

0.01%

ActivePassive International Equity ETF

0%

Invesco Golden Dragon China ETF

0%

SPDR S&P Emerging Asia Pacific ETF

0%

Avantis Emerging Markets Small Cap Equity ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

ALPS Barron's 400 ETF

Anteil0.3%

SPDR S&P Emerging Markets Small Cap ETF

Anteil0.04%

SPDR S&P China ETF

Anteil0.01%

SPDR Portfolio Emerging Markets ETF

Anteil0.01%

ActivePassive International Equity ETF

Anteil0%

Invesco Golden Dragon China ETF

Anteil0%

SPDR S&P Emerging Asia Pacific ETF

Anteil0%

Avantis Emerging Markets Small Cap Equity ETF

Anteil0%

Invesco NASDAQ Future Gen 200 ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten